|
Apr 2
|
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
|
|
Mar 27
|
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
|
|
Jan 16
|
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
|
|
Jan 10
|
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
|
|
Dec 20
|
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
|